UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 215

Sortiert nach

F5‐03‐06: Biomarkers across other neurodegenerative diseases as Parkinson's disease (PD)

Alzheimer's & dementia, 2011-07, Vol.7 (4S_Part_23), p.S811-S811

Kirby, Louis

2011

Volltextzugriff (PDF)

Biomarkers across other neurodegenerative diseases as Parkinson's disease (PD)

Alzheimer's & dementia, 2011-07, Vol.7 (4), p.S811-S811

Kirby, Louis

2011

Volltextzugriff (PDF)

Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline

Alzheimer's & dementia, 2010-11, Vol.6 (6), p.456-464

2010

Volltextzugriff (PDF)

The MARQ-AD: A new measure of interview quality in Alzheimer's disease trials

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S564-S565

2010

Volltextzugriff (PDF)

Scale rating variability in Alzheimer's disease clinical trials: A literature review

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S554-S554

2010

Volltextzugriff (PDF)

The future of blood-based biomarkers for Alzheimer's disease

Alzheimer's & dementia, 2014-01, Vol.10 (1), p.115-131

2014

Volltextzugriff (PDF)

A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment

Neuropsychopharmacology (New York, N.Y.), 2005-06, Vol.30 (6), p.1204-1215

2005

Volltextzugriff (PDF)

Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies

Pain (Amsterdam), 2007-03, Vol.128 (1), p.169-179

2007

Volltextzugriff (PDF)

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders

Current Alzheimer research, 2009-04, Vol.6 (2), p.144

2009

Volltextzugriff (PDF)

A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment

Dementia and geriatric cognitive disorders, 2013-05, Vol.35 (5-6), p.325

2013

Volltextzugriff (PDF)

The lympro® test: A fit for purpose validation of a flow cytometric assay to assess lymphocyte proliferation in peripheral blood lymphocytes in Alzheimer’s disease

Alzheimer's & dementia, 2015-07, Vol.11 (7), p.P849-P849

2015

Volltextzugriff (PDF)

P4‐181: The lympro® test: A fit for purpose validation of a flow cytometric assay to assess lymphocyte proliferation in peripheral blood lymphocytes in Alzheimer's disease

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_18), p.P849-P849

2015

Volltextzugriff (PDF)

A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment

Journal of psychopharmacology (Oxford), 2011-08, Vol.25 (8), p.1020-1029

2011

Volltextzugriff (PDF)

P4‐236: The lympro® test: A biomarker for Alzheimer's disease using blood samples from clinically diagnosed Alzheimer's disease and cognitively intact subjects

Alzheimer's & dementia, 2015-07, Vol.11 (7S_Part_19), p.P870-P871

2015

Volltextzugriff (PDF)

The lympro® test: A biomarker for Alzheimer’s disease using blood samples from clinically diagnosed Alzheimer’s disease and cognitively intact subjects

Alzheimer's & dementia, 2015-07, Vol.11 (7), p.P870-P871

2015

Volltextzugriff (PDF)

Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial

Clinical neuropharmacology, 2009-11, Vol.32 (6), p.311-320

2009

Volltextzugriff (PDF)

Single-Dose Administration of MK-0657, an NR2B-Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease

Journal of clinical pharmacology, 2009-07, Vol.49 (7), p.856-864

2009

Volltextzugriff (PDF)

Guest authorship, mortality reporting, and integrity in rofecoxib studies

JAMA : the journal of the American Medical Association, 2008-08, Vol.300 (8), p.901

2008

Volltextzugriff (PDF)

Guest authorship, mortality reporting, and integrity in rofecoxib studies

JAMA : the journal of the American Medical Association, 2008-08, Vol.300 (8), p.901; author reply 904

Patrono, Carlo

2008

Volltextzugriff (PDF)

Biomarker Qualification in Alzheimer's Disease

Alzheimer's & dementia, 2011-07, Vol.7 (4), p.S330-S330

2011

Volltextzugriff (PDF)

P2‐071: Biomarker Qualification in Alzheimer's Disease

Alzheimer's & dementia, 2011-07, Vol.7 (4S_Part_10), p.S330-S330

2011

Volltextzugriff (PDF)

P3‐349: Scale rating variability in Alzheimer's disease clinical trials: A literature review

Alzheimer's & dementia, 2010-07, Vol.6 (4S_Part_18), p.S554-S554

2010

Volltextzugriff (PDF)

P3‐383: The MARQ‐AD: A new measure of interview quality in Alzheimer's disease trials

Alzheimer's & dementia, 2010-07, Vol.6 (4S_Part_18), p.S564-S565

2010

Volltextzugriff (PDF)

Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease

Movement disorders, 2007-02, Vol.22 (3), p.359-365

2007

Volltextzugriff (PDF)

Long-term Maintenance Treatment of Restless Legs Syndrome With Gabapentin Enacarbil: A Randomized Controlled Study

Mayo Clinic proceedings, 2010-06, Vol.85 (6), p.512-521

2010

Volltextzugriff (PDF)

1 – 25 von 215

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(163)
Mit Volltextzugriff
(194)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(100)
Life Sciences & Biomedicine
(76)
Humans
(63)
Female
(45)
Male
(36)
Biological And Medical Sciences
(31)
Animals
(22)
Middle Aged
(21)
Education
(20)
Fundamental And Applied Biological Sciences. Psychology
(18)
Adult
(17)
Medical Sciences
(17)
Formal Education
(16)
Pedagogy
(16)
Students
(16)
Academic Communities
(15)
Aged
(15)
At Risk Students
(15)
Mathematics Education
(13)
Pregnancy
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

F5‐03‐06: Biomarkers across other neurodegenerative diseases as Parkinson's disease (PD)

Biomarkers across other neurodegenerative diseases as Parkinson's disease (PD)

Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline

The MARQ-AD: A new measure of interview quality in Alzheimer's disease trials

Scale rating variability in Alzheimer's disease clinical trials: A literature review

The future of blood-based biomarkers for Alzheimer's disease

A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment

Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders

A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment

The lympro® test: A fit for purpose validation of a flow cytometric assay to assess lymphocyte proliferation in peripheral blood lymphocytes in Alzheimer’s disease

P4‐181: The lympro® test: A fit for purpose validation of a flow cytometric assay to assess lymphocyte proliferation in peripheral blood lymphocytes in Alzheimer's disease

A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment

P4‐236: The lympro® test: A biomarker for Alzheimer's disease using blood samples from clinically diagnosed Alzheimer's disease and cognitively intact subjects

The lympro® test: A biomarker for Alzheimer’s disease using blood samples from clinically diagnosed Alzheimer’s disease and cognitively intact subjects

Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial

Single-Dose Administration of MK-0657, an NR2B-Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease

Guest authorship, mortality reporting, and integrity in rofecoxib studies

Guest authorship, mortality reporting, and integrity in rofecoxib studies

Biomarker Qualification in Alzheimer's Disease

P2‐071: Biomarker Qualification in Alzheimer's Disease

P3‐349: Scale rating variability in Alzheimer's disease clinical trials: A literature review

P3‐383: The MARQ‐AD: A new measure of interview quality in Alzheimer's disease trials

Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease

Long-term Maintenance Treatment of Restless Legs Syndrome With Gabapentin Enacarbil: A Randomized Controlled Study

Suchergebnisse filtern